Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 80,000 shares at $47.28 ($3.8M) on 2024-09-04, disclosed to the SEC on 2024-09-06.
Scheduled sale ($3.8M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $47.28 | 25,641 | $1.2M | 31.8% |
| 2 | $47.28 | 25,641 | $1.2M | 31.8% |
| 3 | $48.23 | 14,359 | $693K | 18.2% |
| 4 | $48.23 | 14,359 | $693K | 18.2% |
| Total | $47.62 avg | 80,000 | $3.8M | 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |